Year: 2022
Type: review
Study design: Systematic Review
Abstract: BACKGROUND: Valid outcome measures are imperative to evaluate treatment response, yet the suitability of existing end-points for severe asthma is unclear. This review aimed to identify outcome measures for severe asthma and appraise the quality of their measurement properties. METHODS: A literature search was performed to identify "candidate" outcome measures published between 2018 and 2020. A modified Delphi exercise was conducted to select "key" outcome measures within healthcare professional, patient, pharmaceutical and regulatory stakeholder groups. Initial validation studies for "key" measures were rated against modified quality criteria from COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN). The evidence was discussed at multi-stakeholder meetings to ratify "priority" outcome measures. Subsequently, four bibliographic databases were searched from inception to 20 July 2020 to identify development and validation studies for these end-points. Two reviewers screened records, extracted data, assessed their methodological quality and graded the evidence according to COSMIN. RESULTS: 96 outcome measures were identified as "candidates", 55 as "key" and 24 as "priority" for severe asthma, including clinical, healthcare utilisation, quality of life, asthma control and composite. 32 studies reported measurement properties of 17 "priority" end-points from the latter three domains. Only the Severe Asthma Questionnaire and Childhood Asthma Control Test were developed with input from severe asthma patients. The certainty of evidence was "low" to "very low" for most "priority" end-points across all measurement properties and none fulfilled all quality standards. CONCLUSIONS: Only two outcome measures had robust developmental data for severe asthma. This review informed development of core outcome measures sets for severe asthma.
Source: European Respiratory Journal
Authors: Anna Rattu, Ekaterina Khaleva, Chris Brightling, Sven-Erik Dahlén, Apostolos Bossios, Louise Fleming, Kian Fan Chung, Erik Melén, Ratko Djukanovic, Rekha Chaudhuri, Andrew Exley, Gerard H. Koppelman, Arnaud Bourdin, Franca Rusconi, Celeste Porsbjerg, Courtney Coleman, Clare Williams, Hanna Nielsen, Elizabeth Davin, Phil Taverner, Sofia Romagosa Vilarnau, Graham Roberts
Institutions: University of Southampton, University of Leicester, NIHR Leicester Biomedical Research Centre, Karolinska University Hospital, Karolinska Institutet, Imperial College London, Stockholm South General Hospital, University Hospital Southampton NHS Foundation Trust, NIHR Southampton Biomedical Research Centre, University of Glasgow, University Medical Center Groningen, University of Groningen, Université de Montpellier, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Azienda USL Toscana Nord Ovest, European Lung Foundation, European Federation of Allergy and Airways Diseases Patients Associations
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, Chiesi Farmaceutici, European Respiratory Society, Regeneron Pharmaceuticals, European Federation of Pharmaceutical Industries and Associations, National Institute for Health and Care Research, Asthma and Lung UK, University of Southampton, European Commission, Shionogi, National Institutes of Health, Genentech, Horizon 2020 Framework Programme, Medical Research Council, Engineering and Physical Sciences Research Council
OpenAlex ID: W4312113088